Liberyx Therapeutics

Innovative Drug Development Company With Platform Drug
Assets Targeting Pediatric Rare Diseases.

Differentiated IP base

Strong IP rights with solid preclinical data and publications supported by continuous efforts in consolidating IP values such as orphan drug designations

Novelty in Composition

Disease-modifying mechanism via
innovative pharmacokinetic effects and safe with newly created molecular compounds from natural ingredients

Unmet Needs

Growing world-wide patient population of certain rare CNS indications without effective disease-modifying treatment available

Seasoned Team

Curyx and its portfolio companies have award-winning scientific teams widely recognized in neuroscience field & experienced management team with track record founding biotech companies and financial services background

High ROI

Achieving pricing advantages by targeting rare disease indications for orphan drug privileges with minimal capital deployed in a short-term investment horizon, combined with limited competition

Who We Are

As one of the portfolio drug development companies under Curyx Partners platform, Liberyx Therapeutics is dedicated to develop innovative drugs for rare pediatric diseases. Not all drug development is the same. Our approach is very unique in that we try to bring technologies that can be quickly commercialized with patient-friendly administration in highly unmet areas of rare indications, such as rare pediatric metabolic disorders.

Furthermore, our business model enables us to, firstly use minimal amount of capital in a highly efficient manner to reach milestones and, secondly create substantive inflection points at early phases which will reflect significant corporate values to commercialize our drug candidates quickly to make them available for our patients.”

Events

Liberyx Therapeutics Completes Series A Fundraising

May 06, 2022, 06:42 GMT

With multiple promising candidates for rare neurometabolic disorders, Liberyx Therapeutics is at the forefront of developing safe and efficacious therapies for our patients. 

For Any Queries,
Chat With Us

Our Offices:
Hong Kong
Liberyx Therapeutics Limited

Unit 805, 8/F Mirror Tower, 61 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong

USA
Curyx Partners LLC

140 E. Ridgewood Avenue Suite 415, South Tower Paramus NJ 07652 US

Email:

info@curyxpartners.com

Call Us:

+852 21559599

Skip to content